Lance A. Berry Sells 3,259 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry sold 3,259 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $89,003.29. Following the completion of the transaction, the chief financial officer now owns 75,805 shares in the company, valued at $2,070,234.55. The trade was a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Artivion Stock Down 0.9 %

AORT traded down $0.22 on Wednesday, reaching $25.34. The company’s stock had a trading volume of 295,834 shares, compared to its average volume of 385,115. The stock has a 50 day moving average of $29.68 and a two-hundred day moving average of $27.83. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -1,268.25 and a beta of 1.75. Artivion, Inc. has a fifty-two week low of $18.38 and a fifty-two week high of $32.33.

Artivion (NYSE:AORT) last released its earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. As a group, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on AORT shares. Oppenheimer boosted their target price on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Needham & Company LLC decreased their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday. JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Finally, Stifel Nicolaus decreased their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday. Five analysts have rated the stock with a buy rating, According to MarketBeat, Artivion has an average rating of “Buy” and a consensus price target of $31.40.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC grew its stake in shares of Artivion by 30.8% in the fourth quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock valued at $1,021,000 after buying an additional 8,404 shares in the last quarter. Tidal Investments LLC increased its position in shares of Artivion by 14.5% during the fourth quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock worth $5,141,000 after buying an additional 22,804 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Artivion during the fourth quarter worth $64,000. Point72 Asset Management L.P. purchased a new stake in shares of Artivion during the 4th quarter worth approximately $5,573,000. Finally, ProShare Advisors LLC grew its holdings in Artivion by 44.7% during the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock valued at $341,000 after buying an additional 3,683 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.